Table 4.

Adverse events observed in patients with advanced hepatocellular carcinoma treated with sorafenib and cisplatin by transcatheter arterial infusion (TAI) (n = 20)

Characteristic	Level 1						Level 2						Level 3						Total
No. of pts	n = 7				%	%	n = 3				%	%	n = 10				%	%	%	%
Grade (CTCAE v.3.0)	1	2	3	4	Any	3/4	1	2	3	4	Any	3/4	1	2	3	4	Any	3/4	Any	3/4
Leukopenia	3	0	1	0	57	14	0	2	0	0	33	0	2	3	1	0	60	10	55	10
Neutropenia	2	0	1	0	43	14	1	1	0	0	66	0	3	1	0	0	40	0	45	5
Anemia	1	1	2	0	57	29	1	0	0	0	33	0	2	0	1	0	30	10	35	15
Thrombocytopenia	1	2	1	0	57	14	0	2	0	0	66	0	1	6	1	0	80	10	70	10
Hyperbilirubinemia	4	2	0	0	86	29	3	0	0	0	33	0	3	4	0	0	70	0	80	0
AST increased	0	2	1	1	57	29	0	1	2	0	100	66	2	6	2	0	100	20	85	30
ALT increased	1	0	2	0	43	29	1	1	1	0	100	33	2	2	1	0	50	10	55	20
γ-GT increased	0	2	0	1	43	14	0	1	0	0	33	33	0	3	1	0	40	10	40	10
ALP increased	2	0	1	0	43	14	1	1	0	0	66	0	2	1	1	0	40	10	45	10
Amylase increased	0	0	0	1	14	14	0	1	0	0	33	0	3	0	5	0	80	50	50	30
Lipase increased	0	0	0	1	14	14	1	0	1	0	66	33	2	0	1	3	60	10	45	30
Anorexia	2	1	0	0	43	0	0	0	0	0	0	0	2	1	1	0	40	10	35	5
Nausea	1	0	0	0	14	0	0	0	0	0	0	0	2	0	1	0	30	10	20	5
Hypertension	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	20	10	10	5
Gastrointestinal bleeding	0	0	1	0	14	14	0	0	0	0	0	0	0	0	1	0	10	10	10	10
Bacteremia	0	0	1	0	14	14	0	0	0	0	0	0	0	0	0	0	0	0	5	5

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse Events; γ-GT, γ-glutamyl transpeptidase.